March 31, 2025 — A new interview with ConscienHealth founder Ted Kyle offers a long view of more than two decades of work on obesity. The interview explores a core question that people ask all the time: Are we making progress in flipping the script on obesity? Or are we still fighting the same misunderstanding of obesity that has […]
March 29, 2025 — These are indeed interesting times for folks who care about the need that so many people have for obesity care. Medicines for obesity, with the advent of GLP-1 agonists, have become much better. Thus the demand for metabolic surgery has slipped a bit. Most metabolic surgeons have seen this in the volume of cases that […]
March 27, 2025 — Yesterday in JAMA Network Open, researchers from the University of Michigan published a finding that older Americans say Medicare should indeed cover obesity medicines. Authors Lauren Oshman and colleagues present straightforward conclusions: “In this survey study of older US adults, most participants agreed that Medicare should cover weight management medications and more than half of […]
March 26, 2025 — In the U.S., we are at a critical point for the sourcing obesity medicines. March 19 was the last day that FDA would tolerate large scale compounding of tirzepatide on account of the now resolved shortage of that drug. The same milestone for semaglutide is coming up on May 22. Some people are not happy. […]
March 24, 2025 — There’s no denying it. More people are getting access to care for obesity than ever before. In part this is because health professionals have a range of tools for providing that care. GLP-1 agonists like semaglutide and tirzepatide are a big part of that.But those drugs carry a price tag that is blowing up pharmacy […]
March 17, 2025 — Nothing succeeds like success. And thus, the success of GLP-1 medicines for obesity seems to be prompting a re-ordering of marketing for packaged food. Under the Healthy Choice brand, ConAgra has begun promoting an ON TRACK badge that identifies their meals as “GLP-1 Friendly,” as well as high in fiber and protein. ConAgra Senior VP […]
March 11, 2025 — Drug development is tricky. If you want evidence for just how tricky it is, a quick look at the experience with CagriSema will give you a pretty good idea. Yesterday, Novo Nordisk announced topline results of this drug from their REDEFINE 2 clinical trial. Their press release talked about “superior results” for people with overweight […]
March 6, 2025 — Prices are moving quickly for people seeking obesity treatment with semaglutide and tirzepatide. Last week, Lilly offered another price cut for Zepbound. At the time, we noted inaction from Novo Nordisk on this front. But it barely took a week for this formerly unchallenged market leader to step up and respond with a huge price […]
March 1, 2025 — CDC recently told us that diagnoses of diabetes have been rising – very much in line with the decades-long rise in obesity prevalence. As if that news were not sufficiently troubling, a research letter in JAMA this week tells us that adequate control of diabetes is going down. Most of that decline is happening in […]
February 25, 2025 — A concern is surfacing as obesity treatments become more and more effective. The measurement for success has long been percent weight loss. But thoughtful people have always known that the right target for obesity care was actually improved health. It was okay to focus on weight as a measure of effectiveness when the the effect […]
